Whole blood and serum for immunologic assays. 6.2 Cohort II Immunotherapy will start approximately 2-6 months after completion of chemoradiation therapy. 6.2.1 Pre-treatment evaluation (Screening; within 28 days of first dose) 1. Signe d written informed consent. 2. Complete medical history including prior and concurrent medications/treatments. 3. Complete physical examination including, but not limited to vital signs, height, weight and oxygen saturation. 4. ECOG Performance Status. 5. Tumor Evaluation: Confirmation of diagnosis by histology and confirmation of p16 and HPV -16 and/or -18 (by PCR or ISH assay) positivity. 6. 12-lead ECG (p erformed up to 4 weeks prior to Dose 1). 7. Clinical laboratory testing including, but not limited to: CBC with differential and platelet count, PT, INR/PTT, total serum bilirubin, alkaline phosphatase, AST (SGOT), ALT (SGPT), serum creatinine, serum electrol ytes, serum calcium and serum albumin and CPK Note: If these testing are performed within 28 days prior to study Day 0 as standard of care, the results can be used for screening and eligibility assessment. 8. Serology (HIV Ab, HCV Ab, HBsAg). 9. Serum beta HCG (for women of child bearing potential) 10. Whole blood and serum for baseline immunologic assays. 11. Paraffin -embedded tumor tissue or unstained slides for IHC. If clinical screening labs (CBC and Chemistry) were performed within 72 hours prior to the subject’s first immunotherapy, these labs are not required to be redrawn prior to the subject’s first immunotherapy. 38 Date: 8 April 2016 v 2.1 INO-3112 UPCC # 39313 / Inovio HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol 6.2.2 Visit for Immunotherapy (4 doses Every 3 Weeks ±3 days) The following study evaluations will be performed prior to immunotherapy: 1. Medical/Clinical assessment including concurrent medications/treatments.